Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2017

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2017

Summary

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Tumor protein p53 also known as p53 is any isoform of a protein encoded by TP53 gene. TP53 gene is the most frequently mutated gene in human cancer indicating that the TP53 gene plays a crucial role in preventing cancer formation. Activated p53 binds DNA and activates expression of several genes including microRNA miR-34a, WAF1/CIP1 encoding for p21 and hundreds of other down-stream genes. p21 binds to the G1-S/CDK (CDK4/CDK6, CDK2, and CDK1) complexes (molecules important for the G1/S transition in the cell cycle) inhibiting their activity.

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) pipeline Target constitutes close to 26 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 5, 2 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 5 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Dermatology, Genito Urinary System And Sex Hormones, Immunology, Respiratory and Toxicology which include indications Breast Cancer, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Colorectal Cancer, Fallopian Tube Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Bladder Cancer, Cervical Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Endometrial Cancer, Epithelial Ovarian Cancer, Glioblastoma Multiforme (GBM), Gliosarcoma, Hepatocellular Carcinoma, Melanoma, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Skin Cancer, Soft Tissue Sarcoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Renal Failure (ARF) (Acute Kidney Injury), Adenocarcinoma Of The Gastroesophageal Junction, Alopecia, Anaplastic Astrocytoma, Bacterial Infections, Bile Duct Cancer (Cholangiocarcinoma), Brain Cancer, Brain Tumor, Chemotherapy Effects, Esophageal Cancer, Glioma, Hematological Tumor, Hepatic - Colorectal Metastasis, Kidney Transplant Rejection, Leukemias, Liposarcoma, Malignant Mesothelioma, Malignant Pleural Effusion, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Metastatic Renal Cell Carcinoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Oligodendroglioma, Pediatric Diffuse Intrinsic Pontine Glioma, Primitive Neuroectodermal Tumor (PNET), Recurrent Medulloblastoma, Refractory Medulloblastoma, Renal Cell Carcinoma, Retinoblastoma, Solid Tumor, Thymoma (Thymic Epithelial Tumor), Transitional Cell Cancer (Urothelial Cell Cancer) and Viral Infections.

The latest report Cellular Tumor Antigen p53 - Pipeline Review, H2 2017, outlays comprehensive information on the Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)
- The report reviews Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

Introduction
Global Markets Direct Report Coverage
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Overview
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Companies Involved in Therapeutics Development
Aprea AB
CanBas Co Ltd
Critical Outcome Technologies Inc
Innovation Pharmaceuticals Inc
ORCA Therapeutics BV
OSE Immunotherapeutics
Quark Pharmaceuticals Inc
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Drug Profiles
APR-246 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATRN-502 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
contusugene ladenovec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
COTI-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
D-12PGJ3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate p53 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Kevetrin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MHY-449 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MJ-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MX-225 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oncolytic Viruses to Activate p53 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OSE-2101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
p28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QPAL-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QPI-1002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Activate p53 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SGT-53 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate p53 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target Cdk2, Cdk4, Cdk6, Cyclin D1, Cyclin B1, Cdc2, p53 and p16 for Bacterial Infections and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate p53 for Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate p53 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate p53 for Oncology and Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate p53 for Skin Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Cellular Tumor Antigen p53 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZMC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Dormant Products
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Discontinued Products
Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Product Development Milestones
Featured News & Press Releases
Oct 16, 2017: Karolinska Developments portfolio company Aprea announces first patient enrolled in clinical phase 1b/2 study with APR-246 for the treatment of esophageal cancer
Oct 11, 2017: Critical Outcome Technologies Announces First Patient Dosed in Phase 1 Trial of COTI-2 in Head and Neck Squamous Cell Carcinoma
Sep 14, 2017: Innovation Pharmaceuticals Opens New Clinical Site for Novel p53 Drug Candidate in Phase 2 Ovarian Cancer Trial
Sep 11, 2017: Stemline Therapeutics Presents SL-801 Phase 1 Data at ESMO 2017
Aug 30, 2017: Stemline Therapeutics to Present SL-801 Phase 1 Data at Upcoming ESMO Congress
Aug 14, 2017: Critical Outcome Technologies Completes Phase 1 Dose Escalation Portion of COTI-2 Trial in Gynecological Malignancies
Aug 02, 2017: Karolinska Development company Aprea Therapeutics announces First Patient Enrolled in Phase Ib/II Clinical Study
Jul 27, 2017: Quark Pharmaceuticals Reports Positive Results from a Phase 2 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Acute Kidney Injury (AKI) in Subjects at High Risk of AKI Following Cardiac Surgery
Jun 23, 2017: OSE Immunotherapeutics Announces Temporary Pause of Patient Accrual While Continuing Treatment for Patients Already Enrolled In Phase 3 Clinical Trial of Tedopi in Advanced Lung Cancer
May 30, 2017: Cellceutix Anti-Cancer Drug Candidates p53 Activity in Acute Myeloid Leukemia to be Presented by Independent Researchers at the 2017 European Hematology Association Annual Meeting
May 23, 2017: Aprea Therapeutics Announces First Patients Enrolled in Phase Ib/II Clinical Study of APR-246 for the Treatment of Myelodysplastic Syndrome
Apr 03, 2017: Cellceutix AACR Poster Presents Data Supporting Kevetrin Modulation of p53 in Multiple Human Ovarian Cancer Cell-lines and Corresponding Xenograft Tumors
Mar 03, 2017: Cellceutix Provides Update on Developing p53 Drug Candidate Kevetrin as an Oral Anti-Cancer Agent
Feb 21, 2017: Stemline Therapeutics Provides Update on SL-801
Feb 10, 2017: Cellceutix Announces Initiation of Main Clinical Site for Phase 2a Trial of p53 Drug Candidate Kevetrin in the Treatment of Platinum-Resistant/Refractory Ovarian Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables


Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Aprea AB, H2 2017
Pipeline by CanBas Co Ltd, H2 2017
Pipeline by Critical Outcome Technologies Inc, H2 2017
Pipeline by Innovation Pharmaceuticals Inc, H2 2017
Pipeline by ORCA Therapeutics BV, H2 2017
Pipeline by OSE Immunotherapeutics, H2 2017
Pipeline by Quark Pharmaceuticals Inc, H2 2017
Dormant Products, H2 2017
Dormant Products, H2 2017 (Contd..1), H2 2017
Dormant Products, H2 2017 (Contd..2), H2 2017
Dormant Products, H2 2017 (Contd..3), H2 2017
Dormant Products, H2 2017 (Contd..4), H2 2017
Discontinued Products, H2 2017

List Of Figures


Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Cholangiocellular Hepatoma Global Clinical Trials Review, H2, 2018

Cholangiocellular Hepatoma Global Clinical Trials Review, H2, 2018The clinical trial report, Cholangiocellular Hepatoma Global Clinical Trials Review, H2, 2018 provides an overview of Cholangiocellular Hepatoma clinical trials scenario. This report

USD 2500 View Report

Metastatic Hepatocellular Carcinoma - Market Insight, Epidemiology and Market Forecast - 2028

Metastatic Hepatocellular Carcinoma - Market Insight, Epidemiology and Market Forecast - 2028 report provides a detailed analysis of the Metastatic Hepatocellular Carcinoma epidemiology and market outlook for

USD 6250 View Report

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2018

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2018Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein

USD 3500 View Report

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H1 2018

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H1 2018Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein

USD 3500 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available